COVAXIN overall 77.8% effective in Phase-3 trial : Bharat Biotech

Bharat Biotech's Covaxin is overall 77.8 percent effective against Covid, the vaccine maker tweeted today, citing the data from the third phase of clinical trials.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting